Premium
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Author(s) -
Russo Roberto,
Cozzani Emanuele,
Gasparini Giulia,
Parodi Aurora
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13190
Subject(s) - bullous pemphigoid , medicine , pemphigus vulgaris , immunology , pemphigoid , monoclonal antibody , interleukin , atopic dermatitis , dupilumab , interleukin 4 receptor , interleukin 17 , receptor , monoclonal , pemphigus , immunotherapy , dermatology , cytokine , antibody , immune system
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type‐2 response. Treatment of these conditions is often challenging. Dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin‐4 receptor IL‐4Rα, has the potential to inhibit both IL‐4 and IL‐13. We propose IL‐4Rα as a theoretical drug target for cutaneous autoimmune bullous diseases.